A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Published:2014-02 Issue:1 Volume:37 Page:19-23
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Hong Yong Sang,Lee Sung Sook,Kim Kyu-pyo,Lee Jae-Lyun,Kang Yoon-Koo,Shin Sang Joon,Ahn Joong Bae,Jung Kyung Hae,Im Seock-Ah,Kim Tae-You,Kim Jee Hyun,Park Young Suk,Kim Tae Won

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference1 articles.

1. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.;Culy;Drugs,2000

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy;Lung Cancer;2022-06

2. Mobocertinib. EGFR ex20ins-specific tyrosine kinase inhibitor, Treatment for non-small cell lung cancer;Drugs of the Future;2022

3. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study;Journal of Clinical Oncology;2021-10-20

4. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis;Cancer Research and Treatment;2021-07-15

5. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review;PLOS ONE;2021-03-08